Species |
Human |
Protein Construction |
GUCY2C/Guanylyl cyclase C (Ser24-Gln430) Accession # P25092-1 |
His |
Avi |
N-term |
|
C-term |
|
Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Immobilized GUCY2C/Guanylyl cyclase C, His & Avi, Human (Cat.No.: Z03911) at 5 μg/ml (100μl/Well) on the plate can bind Anti-GUCY2C Antibody, hFc Tag |
Expression System |
HEK293 |
Theoretical Molecular Weight |
48.8 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

Immobilized GUCY2C/Guanylyl cyclase C, His & Avi, Human at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-GUCY2C Antibody, hFc Tag with the EC50 of 8.9 ng/ml determined by ELISA.

The purity of GUCY2C/Guanylyl cyclase C, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

GUCY2C/Guanylyl cyclase C, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Target Background |
Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy. |
Synonyms |
Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.